BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2024-03

191 industry Phase 2/3 trial readout(s) and 56 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2024-02 | 2024-04 →

FDA decision events

DateEventStatusCompanyDrugSource
2024-03-01FDA approvalapprovedLANTHEUS MEDCL LNTHDEFINITY; DEFINITY RTApproved 2024-03-01: DEFINITY; DEFINITY RT (NDA021064 SUPPL33)
2024-03-01FDA approvalapprovedGENENTECH INCXOFLUZAApproved 2024-03-01: XOFLUZA (NDA210854 SUPPL20)
2024-03-01FDA approvalapprovedJANSSEN BIOTECHRYBREVANTApproved 2024-03-01: RYBREVANT (BLA761210 SUPPL3)
2024-03-01FDA approvalapprovedGENENTECH INCXOFLUZAApproved 2024-03-01: XOFLUZA (NDA214410 SUPPL6)
2024-03-04FDA approvalapprovedHARROW EYE HROWBYQLOVIApproved 2024-03-04: BYQLOVI (NDA218158 ORIG1)
2024-03-05FDA AdComheldAdCom 2024-03-05: Vaccines and Related Biological Products Advisory Committee
2024-03-05FDA AdComheldLumicell, Inc.AdCom 2024-03-05: Medical Imaging Drugs Advisory Committee - NDA 214511
2024-03-05FDA approvalapprovedFRESENIUS KABI USATYENNEApproved 2024-03-05: TYENNE (BLA761275 ORIG1)
2024-03-05FDA approvalapprovedAMGEN AMGNPROLIA; XGEVAApproved 2024-03-05: PROLIA; XGEVA (BLA125320 SUPPL213)
2024-03-05FDA approvalapprovedSANDOZ INCJUBBONTI; WYOSTApproved 2024-03-05: JUBBONTI; WYOST (BLA761362 ORIG1)
2024-03-06FDA approvalapprovedWYETH PHARMS INCBESPONSAApproved 2024-03-06: BESPONSA (BLA761040 SUPPL3)
2024-03-06FDA approvalapprovedBRISTOL MYERS SQUIBB BMYOPDIVOApproved 2024-03-06: OPDIVO (BLA125554 SUPPL125)
2024-03-07Complete response lettercomplete responseAccord Healthcare Inc.Bendamustine Hydrochloride injectionCRL 2024-03-07: Accord Healthcare Inc. NDA 215749 (Bendamustine Hydrochloride injection)
2024-03-07FDA approvalapprovedPFIZER PFETALZENNAApproved 2024-03-07: TALZENNA (NDA217439 ORIG1)
2024-03-07FDA approvalapprovedGENZYME CORPCAPRELSAApproved 2024-03-07: CAPRELSA (NDA022405 SUPPL22)
2024-03-07FDA approvalapprovedBEONE MEDICINES USA ONCBRUKINSAApproved 2024-03-07: BRUKINSA (NDA213217 SUPPL11)
2024-03-08Complete response lettercomplete responseMapi Pharma Ltd.glatiramer acetate epiCRL 2024-03-08: Mapi Pharma Ltd. NDA 218223 (glatiramer acetate epi)
2024-03-08FDA approvalapprovedREGENERON PHARMACEUTICALS REGNPRALUENTApproved 2024-03-08: PRALUENT (BLA125559 SUPPL39)
2024-03-08FDA approvalapprovedNOVO NVOWEGOVY WEGOVY FLEXTOUCH WEGOVY HDApproved 2024-03-08: WEGOVY; WEGOVY FLEXTOUCH; WEGOVY HD (NDA215256 SUPPL11)
2024-03-13FDA approvalapprovedBEIGENETEVIMBRAApproved 2024-03-13: TEVIMBRA (BLA761232 ORIG1)
2024-03-13FDA approvalapprovedMIRUM MIRMLIVMARLIApproved 2024-03-13: LIVMARLI (NDA214662 SUPPL5)
2024-03-14FDA AdComheldGeron Corporation GERNAdCom 2024-03-14: Oncologic Drugs Advisory Committee - NDA 217779
2024-03-14FDA approvalapprovedACTAVISCABAZITAXELApproved 2024-03-14: CABAZITAXEL (NDA207970 ORIG1)
2024-03-14FDA approvalapprovedMADRIGAL MDGLREZDIFFRAApproved 2024-03-14: REZDIFFRA (NDA217785 ORIG1)
2024-03-15FDA AdComheldCelgene Corp., a Bristol-Myers Squibb Co.; Janssen Biotech, Inc.AdCom 2024-03-15: Oncologic Drugs Advisory Committee - sBLA 125736, sBLA 125746
2024-03-15FDA approvalapprovedJANSSEN PRODSEDURANTApproved 2024-03-15: EDURANT (NDA202022 SUPPL22)
2024-03-15FDA approvalapprovedJANSSEN PRODSEDURANTApproved 2024-03-15: EDURANT (NDA202022 SUPPL20)
2024-03-15FDA approvalapprovedIPSEN INCINCRELEXApproved 2024-03-15: INCRELEX (BLA021839 SUPPL31)
2024-03-15FDA approvalapprovedJANSSEN PRODSEDURANT PEDApproved 2024-03-15: EDURANT PED (NDA219016 ORIG1)
2024-03-15FDA approvalapprovedPARATEK PHARMSXHANCEApproved 2024-03-15: XHANCE (NDA209022 SUPPL19)
2024-03-18FDA approvalapprovedBOEHRINGER INGELHEIM PHARMACEUTICALS INCSPEVIGOApproved 2024-03-18: SPEVIGO (BLA761244 SUPPL3)
2024-03-19FDA approvalapprovedTAKEDA PHARMS USA TAKICLUSIGApproved 2024-03-19: ICLUSIG (NDA203469 SUPPL37)
2024-03-19FDA approvalapprovedIDORSIATRYVIOApproved 2024-03-19: TRYVIO (NDA217686 ORIG1)
2024-03-21FDA AdComheldAdCom 2024-03-21: Ophthalmic Devices Panel of the Medical Devices Advisory Committee
2024-03-21FDA approvalapprovedITALFARMACO SPADUVYZATApproved 2024-03-21: DUVYZAT (NDA217865 ORIG1)
2024-03-22Complete response lettercomplete responseRegeneron Pharmaceuticals, Inc. REGN(odronextamab)CRL 2024-03-22: Regeneron Pharmaceuticals, Inc. BLA 761303/Original 2 ((odronextamab))
2024-03-22Complete response lettercomplete responseCipla USA, Inc.CRL 2024-03-22: Cipla USA, Inc. NDA 210168
2024-03-22Complete response lettercomplete responseRegeneron Pharmaceuticals, Inc. REGNCRL 2024-03-22: Regeneron Pharmaceuticals, Inc. BLA 761303/Original 1
2024-03-22FDA approvalapprovedESPERION THERAPS INCNEXLETOLApproved 2024-03-22: NEXLETOL (NDA211616 SUPPL12)
2024-03-22FDA approvalapprovedESPERION THERAPS INCNEXLETOLApproved 2024-03-22: NEXLETOL (NDA211616 SUPPL13)
2024-03-22FDA approvalapprovedESPERION THERAPS INCNEXLIZETApproved 2024-03-22: NEXLIZET (NDA211617 SUPPL16)
2024-03-22FDA approvalapprovedESPERION THERAPS INCNEXLIZETApproved 2024-03-22: NEXLIZET (NDA211617 SUPPL17)
2024-03-22FDA approvalapprovedIMMUNOGEN INCELAHEREApproved 2024-03-22: ELAHERE (BLA761310 SUPPL5)
2024-03-22FDA approvalapprovedACTELIONOPSYNVIApproved 2024-03-22: OPSYNVI (NDA218490 ORIG1)
2024-03-22FDA approvalapprovedASTRAZENECA AZNBRILINTAApproved 2024-03-22: BRILINTA (NDA022433 SUPPL35)
2024-03-22FDA approvalapprovedALEXION PHARMULTOMIRISApproved 2024-03-22: ULTOMIRIS (BLA761108 SUPPL26)
2024-03-26Complete response lettercomplete responseGan & Lee PharmaceuticalsCRL 2024-03-26: Gan & Lee Pharmaceuticals BLA 761357
2024-03-26FDA approvalapprovedMERCK SHARP DOHME MRKWINREVAIRApproved 2024-03-26: WINREVAIR (BLA761363 ORIG1)
2024-03-27Complete response lettercomplete responseBaxter Healthcare Corporation BAXCRL 2024-03-27: Baxter Healthcare Corporation NDA 218408
2024-03-27FDA approvalapprovedGILEAD SCIENCES INC GILDVEMLIDYApproved 2024-03-27: VEMLIDY (NDA208464 SUPPL16)
2024-03-27FDA approvalapprovedGILEAD SCIENCES INC GILDVEMLIDYApproved 2024-03-27: VEMLIDY (NDA208464 SUPPL17)
2024-03-27FDA approvalapprovedAKEBIA AKBAVAFSEOApproved 2024-03-27: VAFSEO (NDA215192 ORIG1)
2024-03-29Complete response lettercomplete responseBaxter Healthcare Corporation BAXCRL 2024-03-29: Baxter Healthcare Corporation NDA 218224
2024-03-29Complete response letterapproved sinceFidelity BioPharma Co. FISOntralfy (tizanidine) oral solution, 2 mg/5 mLCRL 2024-03-29: Fidelity BioPharma Co. NDA 216190 (Ontralfy (tizanidine) oral solution, 2 mg/5 mL)
2024-03-29FDA approvalapprovedALEXION PHARMS INCVOYDEYAApproved 2024-03-29: VOYDEYA (NDA218037 ORIG1)
2024-03-29FDA approvalapprovedLABS FARMS ROVI SARISVANApproved 2024-03-29: RISVAN (NDA214835 ORIG1)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2024-03 est.P2United BioPharma UTHRNCT03164447 UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection PatientsHIV-1 Infectionunknown10
2024-03 est.P2DBV Technologies DBVTNCT04492683 Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in ChildrenCow's Milk Allergyunknown230
2024-03 est.P2Amnio Technology, LLCNCT04667416 Safety and Preliminary Efficacy of PalinGen Flow Amniotic Tissue Allograft in Chronic Ulcers of the Lower ExtremitiesChronic Ulcer of Lower Extremityunknown82
2024-03 est.P2Lutris Pharma Ltd.NCT04759664 LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRCEGFRI Induced Acneiform Lesionsunknown117
2024-03 est.P2CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT05063253 A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 DiabetesType 2 Diabetes Mellitusunknown208
2024-03 est.P2Clinuvel Europe Limited CUVLNCT05159752 A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)Xeroderma Pigmentosumunknown6
2024-03 est.P2Theratocular Biotek Co.NCT05390840 A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related MAge-Related Macular Degenerationunknown36
2024-03 est.P2Cellevolve Bio IncNCT05541549 A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PMLProgressive Multifocal Leukoencephalopathyunknown60
2024-03 est.P2Vyant BioNCT05625568 Study of VYNT-0126 in the Treatment of Rett Syndrome in Adult PatientsRett Syndromeunknown48
2024-03 est.P3EQRx International, Inc.NCT05712941 Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Endometrial Carcinomawithdrawn
2024-03 est.P2Krystal Biotech, Inc. KRYSNCT05735158 Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)Autosomal Recessive Ichthyosisunknown15
2024-03 est.P3AIM Vaccine Co., Ltd.NCT05812014 Clinical Trail of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) in Participants Aged 18 Years and OlderSARS-CoV-2unknown9800
2024-03 est.P2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05863325 A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)Locally Advanced or Metastatic Non-Small Cell Lung Cancerunknown80
2024-03 est.P2Baiya Phytopharm Co., Ltd. BIYANCT05873374 Evaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for COVID-19COVID-19 Vaccine; COVID-19unknown75
2024-03 est.P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05970432 A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic DermatitisAtopic Dermatitisunknown160
2024-03 est.P3Sinocelltech Ltd.NCT06041061 A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 YearsHPV InfectioN; HPV-Related Carcinomaactive not recruiting18000
2024-03-01 est.P3Angionetics Inc.NCT02928094 Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial IschemiaAngina, Stableunknown160
2024-03-01P2USWM CT, LLCNCT03967223 Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid TumorsNeoplasmsactive not recruiting103
2024-03-01P2Cerebral Therapeutics LLCNCT04153175 Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary GeneralizatRefractory Epilepsyterminated30
2024-03-01P2Marker Therapeutics, Inc. MRKRNCT04511130 Efficacy of MT-401 in Patients With AML Following Stem Cell TransplantAcute Myeloid Leukemia; Stem Cell Transplantationterminated92
2024-03-01P1/P2Cerebral Therapeutics LLCNCT04529954 Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF InfusionFocal Epilepsyterminated20
2024-03-01 est.P3Delcath Systems Inc. DCTHNCT05022901 An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular MelanomaMetastatic Ocular Melanoma; Metastatic Uveal Melanomaactive not recruiting30
2024-03-01P1/P2SK Life Science, Inc.NCT05388435 Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors PatientsAdvanced Solid Tumorterminated15
2024-03-01 est.P2Mabwell (Shanghai) Bioscience Co., Ltd.NCT05446688 A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory LymphomaLymphomaunknown40
2024-03-01 est.P2Keymed Biosciences Co.LtdNCT05452343 A Study of CM310 in Subjects With Chronic PruritusChronic Pruritus of Unknown Originunknown50
2024-03-01P2/P3Fenix Innovation GroupNCT05626959 Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum DisorderAutism Spectrum Disordercompleted54
2024-03-01 est.P2Sinovac Life Sciences Co., Ltd.NCT06042764 SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 PatientsInfection of Upper Respiratory Tract Caused by 2019-nCoVunknown150
2024-03-01P3POLYSAN Scientific & Technological Pharmaceutical CompanyNCT06183229 Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and InfluenzaInfluenza; Acute Respiratory Infectioncompleted166
2024-03-01P2USWM CT, LLCNCT06703346 Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic Neoplasmscompleted82
2024-03-04P2Pfizer PFENCT03765073 Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women AnGroup B Streptococcus Infectionscompleted1208
2024-03-04P1/P2EnteromeNCT04116658 First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive GlioblastomaGlioblastoma, Adultcompleted100
2024-03-04P2Gilead Sciences GILDNCT04778410 Study of Magrolimab Combinations in Participants With Myeloid MalignanciesMyeloid Malignanciesterminated54
2024-03-04P3Lyra TherapeuticsNCT05219968 Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in AdultsChronic Sinusitis; Chronic Rhinosinusitis (Diagnosis)completed196
2024-03-04P2Eli Lilly and Company LLYNCT05256654 A Study of LY3561774 in Participants With Mixed DyslipidemiaDyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases; Hyperlipoproteinemiacompleted205
2024-03-04P2Hoffmann-La RocheNCT05307679 A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q SyndromeDup15q Syndrometerminated7
2024-03-04P2Eucure (Beijing) Biopharma Co., LtdNCT05420324 A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal MelanomaMucosal Melanomacompleted20
2024-03-04 est.P3IBSS Biomed S.A.NCT05480462 Immunogenicity and Safety of Vaccine Against Tetanus and Diphtheria.Diphtheria; Tetanusunknown200
2024-03-04P3Alvotech Swiss AG ALVONCT05842213 Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEXRheumatoid Arthritiscompleted502
2024-03-04P1/P2Burgeon Therapeutics Co., Ltd.NCT06491576 A Clinical Trial of BGT-002 Tablets in Subjects With Nonalcoholic SteatohepatitisNASHcompleted48
2024-03-05P2Guangdong Hengrui Pharmaceutical Co., LtdNCT05733533 A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic CoughRefractory Chronic Coughcompleted97
2024-03-05P3SeqirusNCT06015282 The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and OlderInfluenza, Humancompleted7741
2024-03-06P3Boehringer IngelheimNCT01853826 An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Carcinoma, Non-Small-Cell Lungcompleted481
2024-03-06P3Kolon TissueGene, Inc.NCT03291470 Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the KneeDegenerative Osteoarthritiscompleted531
2024-03-06P2Cumberland Pharmaceuticals CPIXNCT03340675 Oral Ifetroban in Subjects With Duchenne Muscular DystrophyDuchenne Muscular Dystrophy Cardiomyopathy; Cardiomyopathy, Dilatedcompleted46
2024-03-06P3Eurofarma Laboratorios S.A.NCT04721548 Treatment of Androgenetic Alopecia in Men for 24 WeeksAlopeciacompleted336
2024-03-06P2Sanofi SNYNCT05245071 Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEANon-squamous Non-small Cell Lung Cancerterminated22
2024-03-06P2SOTIO Biotech AGNCT05619172 A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal CancerColorectal Cancerterminated16
2024-03-06P3Merck Sharp & Dohme LLC MRKNCT05665595 A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV MelanoMelanomaterminated1594
2024-03-06P2Zomagen Biosciences Ltd.NCT05812781 A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic SyndromeCryopyrin Associated Periodic Syndromecompleted7
2024-03-06P3Novo Nordisk A/S NVONCT05823948 A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDSDiabetes Mellitus, Type 2completed51
2024-03-06P2Dr. August Wolff GmbH & Co. KG ArzneimittelNCT05863104 Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary HyperhidrosisPrimary Axillary Hyperhidrosiscompleted44
2024-03-06P3Colgate Palmolive CLNCT06366568 Efficacy of a Eugenol-based Product to Improve the Quality of Toothbrushing and Relieving Gum Discomfort AreasPlaque, Dentalcompleted86
2024-03-07P2Zenith EpigeneticsNCT03901469 A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast CancerTriple Negative Breast Cancerterminated115
2024-03-07P2Contera PharmaNCT03956979 A Study in Parkinson's Disease in Patients With Moderate to Severe DyskinesiaDyskinesiascompleted89
2024-03-07P2Novartis Pharmaceuticals NVSNCT04795466 Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's DiseaseMild Cognitive Impairment; Alzheimer Diseaseterminated34
2024-03-07P2Vifor (International) Inc.NCT04817670 Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell DiseaseSickle Cell Diseasecompleted25
2024-03-07P3AstraZeneca AZNNCT04847232 Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIHyperkalemiaterminated2690
2024-03-07P2TRYP TherapeuticsNCT05035927 Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating DisorderBinge Eating Disordercompleted5
2024-03-07P2Sanofi SNYNCT05237284 Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosisterminated305
2024-03-07P2Crinetics Pharmaceuticals Inc.NCT05361668 Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid SyndromeCarcinoid Syndrome; Carcinoid; Carcinoid Tumor; Carcinoid Tumor of Ileum; Carcinoid Tumor of Cecum; completed36
2024-03-07P3Laboratoires TheaNCT05397600 Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous PatientsGlaucoma; Ocular Hypertensioncompleted684
2024-03-07P3Taisho Pharmaceutical Co., Ltd.NCT05461352 Long-Term Study of TS-142 in Patients with InsomniaPatients with Insomniacompleted401
2024-03-07P3Huons BiopharmaNCT05964257 To Evaluate the Efficacy and Safety of LIZTOX in Subjects with Benign Masseteric HypertrophyBenign Masseteric Hypertrophyunknown188
2024-03-08P2Taiho Oncology, Inc.NCT04601857 Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial CarcinomaAdvanced and Metastatic Urothelial Cancerterminated43
2024-03-08P2UCB Biopharma SRLNCT04875975 A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune EnceLeucine-Rich Glioma Inactivated 1 Autoimmune Encephalitisterminated12
2024-03-08 est.P3Aimei Vacin BioPharm (Zhejiang) Co., Ltd.NCT06044077 A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy PeoplePneumococcal Diseaserecruiting1920
2024-03-08 est.P2Xizang Haisco Pharmaceutical Co., LtdNCT06290375 A Study of HSK21542 in a Peritoneal Dialysis Pruritus Population.Pruritusunknown250
2024-03-10P1/P2BiomX, Inc.NCT05010577 Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary InfectionChronic Pseudomonas Aeruginosa Infection; Cystic Fibrosiscompleted43
2024-03-11P2Immutep S.A.S. IMMPNCT04811027 Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCCHNSCCcompleted171
2024-03-11P3Novo Nordisk A/S NVONCT05053139 A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without InhibitorsHaemophilia A; Haemophilia A With Inhibitorscompleted281
2024-03-11P3Pfizer PFENCT05248997 Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic RhinosinusitisChronic Rhinosinusitis (CRS) With and Without Nasal Polypscompleted261
2024-03-11P1/P2ImmunityBio, Inc. IBRXNCT05370040 THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 VaccinesCOVID-19terminated60
2024-03-11P2Neurocrine Biosciences NBIXNCT05493293 Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset SeizuresFocal Onset Seizure; Focal Onset Epilepsyterminated82
2024-03-11P3Beijing Konruns Pharmaceutical Co., Ltd.NCT05970783 A Study of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory DiseaseChronic Pelvic Painunknown414
2024-03-12P3Zambon SpANCT03656926 Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)Bronchiolitis Obliterans; Chronic Rejection of Lung Transplant; Lung Transplant Rejection; Lung Trancompleted169
2024-03-12P3Shineway Pharmaceutical Co.,LtdNCT03789760 The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) CapsuleVascular Dementiacompleted493
2024-03-12P2GlaxoSmithKlineNCT04420221 Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 6Infections, Soft Tissuecompleted226
2024-03-12P2Sanofi SNYNCT04524689 Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-basedNon-squamous Non-small-cell Lung Cancer (NSQ NSCLC)terminated57
2024-03-12P2Advanced Accelerator ApplicationsNCT04711135 Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLsGastroenteropancreatic Neuroendocrine Tumors; Pheochromocytoma; Paragangliomaactive not recruiting11
2024-03-12P3Novartis Pharmaceuticals NVSNCT04948333 Asciminib Treatment Optimization in ≥ 3rd Line CML-CPChronic Myelogenous Leukemiacompleted199
2024-03-12P2/P3Holostem s.r.l.NCT05111600 Open-label, Pivotal Clinical Trial to Confirm Efficacy and Safety of Autologous Grafts Containing Stem Cells Genetically Modified for Epidermis Restoration in PJunctional Epidermolysis Bullosa Non-Herlitz Typeterminated2
2024-03-12P3Eli Lilly and Company LLYNCT05412004 Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep ApneaObstructive Sleep Apnea; Obesitycompleted469
2024-03-12P3Pfizer PFENCT05540522 A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or OlderInfluenza, Humancompleted45789
2024-03-12P3Merck Sharp & Dohme LLC MRKNCT05818137 A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)Pulmonary Arterial Hypertensioncompleted46
2024-03-13P2IntelGenx Corp.NCT03402503 Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's DiseaseAlzheimer Diseasecompleted52
2024-03-13P3Teva Branded Pharmaceutical Products R&D, Inc.NCT04458857 A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of AgeMigrainecompleted235
2024-03-13 est.P3Eli Lilly and Company LLYNCT04469062 A Study of Mirikizumab (LY3074828) in Participants With Ulcerative ColitisUlcerative Colitiswithdrawn
2024-03-13P2Novartis Pharmaceuticals NVSNCT04926831 Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLCNon-small Cell Lung Cancerterminated4
2024-03-13P2Gannex Pharma Co., Ltd.NCT05190523 Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary CholangitisPrimary Biliary Cholangitiscompleted98
2024-03-13P3UCB Biopharma SRLNCT05514873 An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were PrGeneralized Myasthenia Graviscompleted26
2024-03-13P2Pfizer PFENCT05546476 Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15Non-small Cell Lung Cancer; Pancreatic Cancer; Colorectal Cancer; Loss of Appetite; Fatigue; Cachexicompleted187
2024-03-13P2Brii Biosciences LimitedNCT06057012 A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)Severe Postpartum Depressioncompleted11
2024-03-13P3Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNCT06817187 Clinical Study on the Combined Administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis VaccineStreptococcus Pneumoniae Infectionscompleted1110
2024-03-14P1/P2Cantargia ABNCT03267316 A First-in-Human Study of CAN04 in Patients With Solid Malignant TumorsNon Small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma; Triple Negative Breast Cancer; Coloreccompleted167
2024-03-14P2Insmed Incorporated INSMNCT05176951 A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With InterstitPulmonary Hypertensioncompleted39
2024-03-14P1/P2Enlivex Therapeutics RDO Ltd. ENLVNCT05431907 Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care ChPeritoneal Metastasesterminated9
2024-03-14P2Eli Lilly and Company LLYNCT05563246 A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular EventsLipoprotein Disordercompleted233
2024-03-14P3Tasly Biopharmaceuticals Co., Ltd.NCT05700591 rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)Acute Ischemic Strokecompleted1552
2024-03-14P2Bio 54, LLCNCT06205615 Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154BWound Bleedingcompleted24
2024-03-15P2CellProtheraNCT02669810 EXCELLENT (EXpanded CELL ENdocardiac Transplantation)Acute Myocardial Infarctioncompleted49
2024-03-15P1/P2Eli Lilly and Company LLYNCT04238819 A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including NeurobRelapsed Solid Tumor; Refractory Solid Tumorcompleted47
2024-03-15P2/P3ModernaTX, Inc.NCT04796896 A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of AgeSARS-CoV-2completed11942
2024-03-15P3Laboratorios Silanes S.A. de C.V.NCT04841096 Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment FailureType 2 Diabetescompleted162
2024-03-15P3Axsome Therapeutics, Inc. AXSMNCT05059223 A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With NarcolepsyNarcolepsy; Cataplexy; Excessive Daytime Sleepinesscompleted90
2024-03-15P3Teva Pharmaceuticals USANCT05617820 Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal AtDyspareuniacompleted1050
2024-03-15P3Synlogic SYBXNCT05764239 Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)Phenylketonuriaterminated35
2024-03-17P1/P2Sonnet BioTherapeuticsNCT05435742 SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)Chemotherapy-induced Peripheral Neuropathy (CIPN)terminated9
2024-03-18P3AstraZeneca AZNNCT04494425 Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast CancerAdvanced or Metastatic Breast Canceractive not recruiting866
2024-03-18P2BayerNCT04722991 Non-proliferative Diabetic Retinopathy Treated With RuncaciguatDiabetic Retinopathycompleted109
2024-03-18P3Tasly GeneNet Pharmaceuticals Co., LtdNCT05092841 A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1ACharcot-Marie-Tooth Type 1Acompleted176
2024-03-18P3Nanjing Chia-tai Tianqing PharmaceuticalNCT05450887 Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary CholangitisPrimary Biliary Cholangitiscompleted108
2024-03-18P3Sollis Therapeutics, Inc.NCT05614648 Sciatica Epidural Radiculopathy Experimental New Interventional TherapY Clonidine MicropelletLumbosacral Radiculopathyterminated17
2024-03-18P2Intuitive Surgical ISRGNCT05769257 A Safety and Feasibility Study of IS-001 Injection in Patients Undergoing Robotic Colorectal SurgeryUreter Injurycompleted12
2024-03-18P3Pfizer PFENCT05842967 A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV DiseaseRESPIRATORY SYNCYTIAL VIRUS (RSV)completed885
2024-03-18P3Glaukos Corporation GKOSNCT06061718 Travoprost Intraocular Implant in Conjunction With Cataract SurgeryOpen Angle Glaucoma; Ocular Hypertensionunknown60
2024-03-19P3Biofrontera Inc. BFRINCT03573401 Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With PhotodynamicSuperficial Basal Cell Carcinomaactive not recruiting187
2024-03-19 est.P2MedImmune LLCNCT04145193 Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRCMicrosatellite-stable Colorectal Cancerwithdrawn
2024-03-19P3Hoffmann-La RocheNCT04285567 A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ BendaChronic Lymphocytic Leukemia (CLL)completed166
2024-03-19P210xBio, LLCNCT05154955 A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental FatSubmental Fatcompleted51
2024-03-19P3Novo Nordisk A/S NVONCT05352815 A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in PeopleDiabetes Mellitus, Type 2completed1291
2024-03-19P3AbbVie ABBVNCT05601882 A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants WitAtopic Dermatitiscompleted920
2024-03-19P3Teva Branded Pharmaceutical Products R&D LLCNCT05693935 A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With SSchizophreniacompleted675
2024-03-19P2PharmaMarNCT05705167 Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)COVID-19terminated37
2024-03-19P3Chengdu Brilliant Pharmaceutical Co., Ltd.NCT06092684 The Efficacy and Safety of Esketamine in Elective Laparoscopic SurgeryLaparoscopy; Anesthesia, Intravenouscompleted358
2024-03-20P1/P2Imugene LimitedNCT02795988 A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric CancerGastrointestinal Neoplasms; Adenocarcinomacompleted64
2024-03-20P3Merck Sharp & Dohme LLC MRKNCT03615326 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal JunctGastric Neoplasms; Gastroesophageal Junction Adenocarcinomacompleted738
2024-03-20P2Novartis Pharmaceuticals NVSNCT04589650 Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth SpectrumPIK3CA-related Overgrowth Spectrum (PROS)active not recruiting236
2024-03-20P1/P2Lepu Biopharma Co., Ltd.NCT04843709 A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid TumorsAdvanced or Metastatic Solid Tumorscompleted39
2024-03-20P2Novartis Pharmaceuticals NVSNCT05135000 Study of Efficacy and Safety of LTP001 in Pulmonary Arterial HypertensionPulmonary Arterial Hypertensionterminated47
2024-03-21P1/P2Hoffmann-La RocheNCT03037385 Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other AdvanceRET-altered Non Small Cell Lung Cancer; Medullary Thyroid Cancer; RET-altered Papillary Thyroid Canccompleted590
2024-03-21P2/P3Pfizer PFENCT04804033 A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine PreventionMigraineterminated1753
2024-03-21P2TYK Medicines, IncNCT05146219 Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR MutationNSCLC; EGFR Activating Mutation; Brain Metastases; Leptomeningeal Metastasiscompleted29
2024-03-21P3Endo USA Inc., a Keenova Therapeutics CompanyNCT05254457 Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar FibromatosisPlantar Fibromatosiscompleted145
2024-03-21P3Sumitomo Pharma Co., Ltd.NCT05359081 A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in JapanSchizophreniaterminated68
2024-03-21P3JW PharmaceuticalNCT05814406 To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DMType 2 Diabetes Mellituscompleted196
2024-03-22P2Yiviva Inc.NCT04000737 YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)Advanced Hepatocellular Carcinomacompleted62
2024-03-22P3Bristol-Myers Squibb BMYNCT04026412 A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by SurNon-Small Cell Lung Cancer (NSCLC)completed925
2024-03-22P3Yisheng Biopharma (Singapore) Pte. Ltd.NCT05667974 A Study to Evaluate a PIKA Rabies Vaccine(Vero Cell)for Human Use,Freeze-driedRabies; Preventionunknown4500
2024-03-22P3Chong Kun Dang PharmaceuticalNCT06121518 Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 MonotherapyEssential Hypertensioncompleted235
2024-03-25P1/P2Gilead Sciences GILDNCT02953509 Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's LymphomaNon Hodgkin Lymphomaterminated178
2024-03-25P1/P2AkesoNCT03852251 A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ AdenocarciGastric Adenocarcinoma; Advanced Solid Tumors; Gastroesophageal Junction Adenocarcinomacompleted338
2024-03-25P2Vir Biotechnology, Inc. VIRNCT04412863 Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus InfectionChronic Hepatitis Bcompleted84
2024-03-25P3argenx ARGXNCT04598477 A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)Pemphigus Vulgaris; Pemphigus Foliaceusterminated183
2024-03-25P2Tsumura USANCT04742907 Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel ResectionEnhanced Recovery After Surgerycompleted402
2024-03-25P3Gilead Sciences GILDNCT04778397 Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in PatientAcute Myeloid Leukemiaterminated258
2024-03-25 est.P2Merck Sharp & Dohme LLC MRKNCT05130086 A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)Human Immunodeficiency Virus (HIV) Infectionswithdrawn
2024-03-25 est.P2Ferring PharmaceuticalsNCT05571111 Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs AfterInfertilitywithdrawn
2024-03-25P2DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT05896527 A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque PsoriasisPlaque Psoriasiscompleted229
2024-03-25P2Chengdu Suncadia Medicine Co., Ltd.NCT06051357 Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal Hemoglobinuriacompleted26
2024-03-26P2/P3Staidson (Beijing) Biopharmaceuticals Co., LtdNCT04449588 Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDSCOVID-19 Pneumoniaterminated369
2024-03-26P2Incyte Corporation INCYNCT04629339 Study of INCB086550 in Select Solid TumorsNon Small Cell Lung Cancer; Urothelial Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma; Melanterminated16
2024-03-26P3Vertanical GmbHNCT04940741 Efficacy and Safety of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back PainChronic Non-specific Low Back Paincompleted820
2024-03-26P2/P3BioNTech SE BNTXNCT05472038 A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy IndividualsSARS-CoV-2 Infection; COVID-19completed1453
2024-03-26P3AstraZeneca AZNNCT05573464 A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe ChrChronic Obstructive Pulmonary Disease (COPD)completed559
2024-03-26P2Equillium EQNCT05589610 Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia AreataAlopecia Areata; Alopecia; Alopecia Totalis; Alopecia Universaliscompleted36
2024-03-26P3JW PharmaceuticalNCT05815901 A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout PatientsGoutcompleted612
2024-03-27P3Pfizer PFENCT03000439 A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIAArthritis Juvenile Idiopathiccompleted100
2024-03-27P2Altimmune, Inc. ALTNCT04684914 HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)Hepatitis B, Chronicterminated87
2024-03-27P3Paratek Pharmaceuticals IncNCT04779242 Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial PneumoniaCommunity-acquired Pneumonia; Bacterial Pneumoniacompleted670
2024-03-27P2/P3AstraZeneca AZNNCT04986202 Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%Heart Failure With Preserved Ejection Fractioncompleted711
2024-03-27P3Sanofi Pasteur, a Sanofi Company SNYNCT05437510 Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and RSV Immunization; Healthy Volunteercompleted8057
2024-03-27P3Huahui HealthNCT05787418 HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2COVID-19completed918
2024-03-27 est.P2ImmuneMed, Inc.NCT05808335 A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)Chronic Hepatitis Bunknown32
2024-03-27P2Oculis OCSNCT05896670 Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye DiseaseDry Eye Diseasecompleted122
2024-03-28P2TBF Genie TissulaireNCT05207189 Biological Sling Allograft (UVT) for the Treatment of Urinary Incontinence in Women Presenting With Synthetic Sling ComplicationsFemale Stress Incontinence; Stress Urinary Incontinencecompleted16
2024-03-28P1/P2Sanofi Pasteur, a Sanofi Company SNYNCT05624606 Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and OlderInfluenza Immunizationcompleted682
2024-03-28P1/P2Dermaliq Therapeutics, Inc.NCT05636904 Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in MenAndrogenetic Alopeciacompleted120
2024-03-28 est.P2Keymed Biosciences Co.LtdNCT05671445 The Study of CM326 in Adult Subjects With Atopic DermatitisAtopic Dermatitisunknown100
2024-03-29P3Ferring Ventures LimitedNCT03710876 Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural MesotheliomaMalignant Pleural Mesotheliomacompleted53
2024-03-29P1/P2Keymed Biosciences Co.LtdNCT05324137 A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal PolypsChronic Rhinosinusitis With Nasal Polypscompleted88
2024-03-29 est.P2Shanghai Henlius BiotechNCT05354700 A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung CancerSmall-cell Lung Cancerunknown20
2024-03-29P2Haisco Pharmaceutical Group Co., Ltd.NCT05601778 A Study of HSK31858 in Participants with Non-Cystic Fibrosis BronchiectasisNon-cystic Fibrosis Bronchiectasis (NCFBE)completed226
2024-03-29P2/P3AstraZeneca AZNNCT05648110 Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel AnitCOVID-19, SARS-CoV-2completed3882
2024-03-29P2Janssen Research & Development, LLCNCT05663866 Premedication to Reduce Amivantamab Associated Infusion Related ReactionsCarcinoma, Non-Small-Cell Lungactive not recruiting68
2024-03-29P3Chongqing Claruvis Pharmaceutical Co., Ltd.NCT06499688 A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar LinesModerate to Severe Glabellar Linescompleted529
2024-03-30P3Marinus PharmaceuticalsNCT04391569 Randomized Therapy In Status EpilepticusStatus Epilepticuscompleted100
2024-03-30P2Vicore Pharma ABNCT04533022 Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPFIdiopathic Pulmonary Fibrosiscompleted52
2024-03-30P2Juventas Cell Therapy Ltd.NCT04586478 Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's LymphomaNon-Hodgkin's Lymphomarecruiting60
2024-03-30P2IMMUNOe Research CentersNCT04705831 Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 InfectionPost-Viral Fatigue Syndrome; Post-Viral Disorder (Disorder); Covid19completed40
2024-03-30P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT04856774 Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid TumorsAdvanced Solid Tumorscompleted81
2024-03-30 est.P2Veru Inc. VERUNCT05079360 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast CancerMetastatic Breast Cancerwithdrawn
2024-03-30 est.P2Jiangsu HengRui Medicine Co., Ltd.NCT05333835 A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 DiabetesType 2 Diabetesunknown455
2024-03-30 est.P2Qilu Pharmaceutical Co., Ltd.NCT05799820 QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRCColorectal Carcinomaunknown60
2024-03-31P3GlycoMimetics IncorporatedNCT03616470 Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid LeukemiaAcute Myeloid Leukemiaterminated388
2024-03-31 est.P2DascenaNCT03752489 Unsupervised Machine Learning for Clustering of Septic Patients to Determine Optimal TreatmentSepsis; Severe Sepsis; Septic Shockunknown51645
2024-03-31P3Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT04143607 ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLCLocally Advanced or Metastatic NSCLCunknown337
2024-03-31 est.P2SCM Lifescience Co., LTD.NCT04189432 Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host DiseaseChronic Graft-versus-host-diseaseunknown84
2024-03-31 est.P3Eidos Therapeutics, a BridgeBio companyNCT04418024 Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid PolyneurophathyTransthyretin-Related (ATTR) Familial Amyloid Polyneuropathywithdrawn
2024-03-31 est.P2Cyclo Therapeutics, Inc.NCT05607615 A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's DiseaseAlzheimer's Diseaseunknown90
2024-03-31 est.P1/P2Kang Stem Biotech Co., Ltd.NCT05944627 Evaluate Safety and Explore Efficacy of FURESTEM-OA Kit Inj. in Patients With Knee OsteoarthritisKnee Osteoarthritisunknown68
2024-03-31P3Sanofi Pasteur, a Sanofi Company SNYNCT06228586 Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in VietnamMeningococcal Infection; Healthy Volunteerscompleted447

← 2024-02 | 2024-04 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.